ReviewFrontiers in endocrinology2025
Unraveling the gut microbiota's role in PCOS: a new frontier in metabolic health.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Kefir: A Potential Gut Microbiota Modulator: A Systematic Review of Human Interventional Studies.MicrobiologyOpen · 2026Pooled it
- Effects of probiotic and metformin co-administration versus metformin monotherapy on anthropometric measurements, hormones, and glucolipid profile in women with polycystic ovary syndrome: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Trial
- Article
- Human biomarker navigator.iMeta · 2026Review
- Gut microbiota in PCOS: key microbial changes, potential mechanisms and clinical applications.Journal of translational medicine · 2026Review
- Multi-omics biomarkers in endometrial receptivity: from mechanisms to clinical translation.Journal of translational medicine · 2026Review
- Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety.Diabetes/metabolism research and reviews · 2026Article
- The Role of Antioxidants in the Management of Polycystic Ovary Syndrome.Antioxidants (Basel, Switzerland) · 2026Review
- Exploring gut microbiome alterations and hormonal imbalances in polycystic ovary syndrome: insights from a comparative study.Journal of ovarian research · 2026Article
- Probiotic Modulation of the Gut-Ovary and Gut-Myometrium Axes: An In Vitro Study.Microorganisms · 2026Article
- Lobetyolin reshapes gut microbiota and bile acid metabolism to improve androgen-driven PCOS phenotypes in mice.Frontiers in microbiology · 2026Article
- Natural Products for Polyendocrine Metabolic Ovarian Syndrome: Integrating Traditional Chinese and Western Medicine Perspectives.Drug design, development and therapy · 2026Review
- BMI-stratified phenotypes of polycystic ovary syndrome: advances in gut microbiota research and personalized management strategies.Frontiers in endocrinology · 2026Review
- Gut microbiome dysbiosis in PCOS: from pathogenesis to microbiome-targeted therapies.Frontiers in endocrinology · 2026Review
- Sheep placental extract ameliorates polycystic ovary syndrome in rats by regulating ERβ-mediated Treg cells via the TGF-β1/Smad3 signaling pathway.Frontiers in immunology · 2026Article
- Article
- Article
- Recent advances in gut microbiota-mediated regulation of fat deposition and metabolic disorders.Microbiome research reports · 2025Review
- Gut-ovary axis in polycystic ovary syndrome: mechanistic insights and gut microbiota-targeted therapeutic strategies.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder affecting reproductive-age women, characterized primarily by hyperandrogenism, ovulatory dysfunction, and metabolic abnormalities. In recent years, the gut microbiota has garnered widespread attention for its potential role as a key regulator of host metabolism in the pathogenesis of PCOS. Studies have shown that PCOS patients exhibit dysbiosis in their gut microbiota, characterized by reduced microbial diversity, an imbalance in the ratio of Firmicutes to Bacteroidetes, changes in the abundance of specific taxa, and abnormal levels of metabolic products. These alterations may exacerbate metabolic dysfunction in PCOS through multiple mechanisms, including influencing host energy metabolism, disrupting lipid and bile acid metabolism, and inducing chronic inflammation. Addressing gut dysbiosis through the modulation of patients' microbiomes-such the use of, prebiotics, fecal microbiota transplantation, and optimizing diet lifestyle-may offer strategies for improving metabolic abnormalities and alleviating clinical symptoms in PCOS. Additionally, the gut microbiome promises as a potential marker, aiding in the precise diagnosis and personalization of PCOS. Although our current understanding of how the gut microbiota influences PCOS is still limited, research is needed to explore the causal relationships and mechanisms involved, providing a more reliable theoretical basis for clinical. This review aims summarize the research progress on the relationship between gut microbiota and PCOS, and to suggest future directions to promote the development of prevention and treatment strategies for PCOS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.